All data are based on the daily closing price as of September 5, 2025
s
Sumitomo Pharma Co.
4506.TSE
12.23 USD
1.18
+10.68%
Overview
Last close
12.23 usd
Market cap
4.86B usd
52 week high
12.23 usd
52 week low
1.81 usd
Target price
10.27 usd
Valuation
P/E
30.4882
Forward P/E
20.202
Price/Sales
1.7289
Price/Book Value
4.0826
Enterprise Value
6.73B usd
EV/Revenue
2.4883
EV/EBITDA
17.5111
Key financials
Revenue TTM
2.82B usd
Gross Profit TTM
1.72B usd
EBITDA TTM
414.01M usd
Earnings per Share
0.4 usd
Dividend
N/A usd
Total assets
5.09B usd
Net debt
2.00B usd
About
Sumitomo Pharma Co., Ltd. engages in manufacture, and purchase and sale of pharmaceutical products for medical treatment in Japan, North America, and Asia. The company offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. It also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. Further, the company offers veterinary drugs, medical devices, etc. It has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.